In lung cancer, it can significantly inhibit the proliferation of KRAS mutant lung cancer, downregulate the expression of programmed death-ligand 1 induced by interferon-gamma, and reduce the migration of Lewis lung cancer cells in a CCL2-dependent manner [22–24]. The gene discussed is KRAS; the disease is lung carcinoma.